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Abstract
Background: The amount of data deposited in the Gene Expression Omnibus (GEO) has expanded significantly. It
is important to ensure that these data are properly annotated with clinical data and descriptions of experimental
conditions so that they can be useful for future analysis. This study assesses the adequacy of documented asthma
markers in GEO. Three objective measures (coverage, consistency and association) were used for evaluation of
annotations contained in 17 asthma studies.
Results: There were 918 asthma samples with 20,640 annotated markers. Of these markers, only 10,419 had
documented values (50% coverage). In one study carefully examined for consistency, there were discrepancies in
drug name usage, with brand name and generic name used in different sections to refer to the same drug.
Annotated markers showed adequate association with other relevant variables (i.e. the use of medication only
when its corresponding disease state was present).
Conclusions: There is inadequate variable coverage within GEO and usage of terms lacks consistency. Association
between relevant variables, however, was adequate.
Background
The Gene Expression Omnibus (GEO) project was
initiated by the National Center for Biotechnology Infor-
mation (NCBI) to serve as a repository for gene expres-
sion data [1,2]. In addition to GEO, there are several
other large-scale genetic databases, including ArrayEx-
press, the Center for Information Biology Gene Expres-
sion Database (CIBEX), and the Stanford Tissue
Microarray Database (TMAD), each with similar struc-
tures and purposes [3-5]. Currently, GEO contains over
17,000 experiments and 400,000 samples. There has
been an ever growing interest in large microarray repo-
sitories for several reasons: (a) Microarray data are
required by funding agencies and scientific journals to
be made publicly accessible; (b) such repositories enable
researchers to view data from other research groups;
and (c) with proper pre-processing, such repositories
may allow researchers to formulate and test hypotheses
in a relatively inexpensive manner [6]. There are also
other advantages in pooling data from several studies,
such as providing quantitative researchers with access to
a diverse dataset to verify their algorithms, and to check
consistency of results over a large dataset [7,8].
Although GEO constitutes a major advance to pro-
mote data sharing, it is not without its imperfections,
particularly related with the annotation of data. In late
2001, the Minimum Information About a Microarray
Experiment (MIAME) standard was developed by the
Microarray Gene Expression Databases Society (MGED)
in an effort to standardize the way data were entered in
GEO and other public repositories [9]. Members of the
consortium realized that gene expression data were only
useful if it could be put “…in the context of a detailed
description of conditions under which they were gener-
ated” [9]. This led to MIAME’s basic tenets that all data
be recorded with enough information and detail to
allow samples to be compared to others (and therefore
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information accessible for data mining and other auto-
mated means of analysis. Specifically, MIAME made
provisions for the use of controlled vocabulary (as
opposed to free-text fields), as well as descriptions of
experimental design, array design, samples, hybridiza-
tions, measurements, and normalization [9]. MIAME
does not specify the use of any particular terminology.
However, the use of standard controlled vocabularies is
desirable to promote data exchange.
Several authors, however, have noted flaws in the
practical use of the MIAME standard by researchers.
Galbraith points out that the MIAME standard is lack-
ing in informational content, to the point that a
researcher will have difficulty understanding relevant
factors that contributed to the results generated from
the data [10]. Shields brought out another important
point, namely, that although MIAME may be a good
standard for reporting data, it still falls short of ensuring
that various laboratories have uniform experimentation
techniques [11].
Even after MIAME was implemented, Ioannidis et al.
showed that while some microarray experiments fol-
lowed the MIAME standard, many others did not, and
even those that did often had insufficient information to
recreate experiments and reproduce results [12]. In
addition, because the use of controlled terminology is
not a requirement for MIAME compliance, sample
annotations and experimental design descriptions are
deposited as free text. Thus, it is difficult to ensure and
enforce compliance with MIAME standards.
T h eg o a lo u rs t u d yw a st oa s s e s st h ea d e q u a c yo f
documented information describing data samples in
GEO, specifically in the asthma domain.
Method
We explored the quality of data deposited in GEO for
17 asthma studies. We utilized a toolkit developed for
analysis of gene expression data in GEO, DSGeo [13].
DSGeo contains a browser that renders the studies in
GEO available for text queries. This browser returns
research studies when samples or platforms contain the
search term within sample data or experimental design
descriptions. In order to identify all appropriate studies
for which there were samples in GEO, a text search for
the term “asthma” was used and all studies that were
retrieved were annotated and analyzed. For each study,
all samples were annotated using domain-specific pre-
defined variables. Methods for identifying variables and
re-organizing the information from GEO in a relational
database were previously described [14,15].
The annotation tool used for this research was devel-
oped to facilitate human annotation by allowing easy
access between the data descriptions and measurements
that were downloaded from GEO and appropriate scien-
tific publications from Pubmed [13]. The annotators are
able to read the study descriptions that researchers
deposited in GEO, as well as individual sample descrip-
tions, attached tables and supplementary documents.
Each annotator is given access to full-text electronic
copies of articles, whenever available, to aid in annota-
tion. Figure 1 illustrates the annotation tool used for
assigning values to specified variables for every sample.
Cell line would have values “yes”, “no” or “unknown”.
Annotation training
There were two annotators for this study, both trained
biology students. They underwent an orientation period
to familiarize themselves with the GEO database as well
as tools that were developed to examine the data sam-
ples. They were given time to learn how to use the web
interface, specifically the free-text dialog boxes as well
as the standard radio buttons and drop-down menus
used for annotating most of the variables. In addition,
they were acquainted with the organization of the data-
base, in a way that they would be able to access any
supplemental information essential to completing an
annotation. Techniques such as batch sample annotation
and annotation grouping were also introduced in order
to maximize the efficiency of annotation. To practice,
the annotators (undergraduate students majoring in
biology) were then assigned to annotate a domain which
had already been previously annotated, the breast cancer
domain [14].
As in previous experiments, written instructions were
given to provide the students with an extensive list of
definitions for variables specific to breast cancer and
guidelines on how to annotate them. Once a student
completed the previously annotated breast cancer
domain, the results were analyzed based on the quality
of annotation as well as timeliness of completion. Upon
satisfactory completion, each student was considered eli-
gible to begin data annotation for asthma samples.
Using the same sequence of training steps used for
annotating samples in the breast cancer domain, stu-
dents were assigned asthma studies and samples for
annotation.
Inter-annotator agreement
Inter-annotator agreement was measured using strict
agreement, which measured the total number of annota-
t i o n st h a tw e r ee x a c t l ya l i k eb e t w e e nt h et w oa n n o t a -
tors. Kappa statistical measure was also used to measure
the inter-annotator agreement, taking into account the
probability of agreement due to chance [16]. In the case
of breast cancer, the quality of annotation was measured
by comparing the new annotations to values previously
established [14].
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consisted of 918 samples, ranging from 404 samples in
the largest study to 2 samples in the smallest one. All of
the studies were annotated using 26 different variables.
Inter-annotator agreement was measured between the
two student annotators.
Adequacy of documentation
We examined three primary measures (coverage, consis-
tency, and association) to evaluate the quality of textual
data accompanying data samples. Coverage was defined
as the number of variables that have known values rela-
tive to a sample set. For example, if only 10 of 100 total
samples had known values for the variable ‘gender’, then
coverage was 10%. Consistency was defined as the lack
of variation in term usage for data reporting and publi-
cation (e.g., consistently using the generic name of med-
ications in any data provided by the researchers, rather
than using the trade name in one and the generic name
in another). Association was assessed by measuring how
often appropriate medication use and asthma diagnosis
co-occurred. It was expected that asthma medications
should be used only for samples/patients that had the
diagnosis of asthma.
Results
Breast cancer (training data)
A total of 604 breast cancer samples from two studies
were re-annotated by the two students during the train-
ing phase. There were 41 markers for breast cancer, as
described in reference [14]. The results of these annota-
tions are shown in Table 1.
The 318-sample study contained 12,739 annotations
in total. The total amount of annotations is less than
what would have been 318 samples multiplied by 41
variables because of non-mandatory fields. For
instance, cancer staging is not a mandatory field for
one of two (or more) staging methods used in practice
(e.g. TNM, Duke classification). Thus, leaving one of
these fields blank would lead to fewer annotations for
a given sample. Of the 12,739 annotations, the first
annotator strictly agreed with the previous annotator
on 10,127 annotations, or 79.5% of the time. Kappa
showed moderate agreement, which was assessed to
be sufficient. The 286-sample study had a total of
10,589 annotations. The second annotator agreed with
the previous annotator in 8,567 annotations, or 80.9%
of the time. The kappa measure was 0.401, also show-
ing moderate agreement. This training was assessed to
be sufficient for the students to annotate a new
domain.
Figure 1 Asthma annotation form.
Table 1 Inter-annotator agreement for the breast cancer
domain performed by students in comparison to
previous annotation
Annotator Agreement Type % Agreement Kappa
Annotator 1 N=318 Strict 79.5 0.524
Annotator 2 N=286 Strict 80.9 0.401
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The asthma domain contained 20,640 annotations. Strict
inter-annotator agreement was measured between the
two student annotators, as well as kappa inter-annotator
agreement. The results of this study are noted in Table
2, which shows excellent inter-annotator agreement
between the student annotators. There was 93% strict
agreement between annotators. The kappa measure was
0.859, which corresponds to almost perfect agreement.
There was an early attempt by the NCBI to have
annotations of the data within GEO with the creation of
GEO Data Sets (GDS).(1) This effort was limited, and
there remains a majority of the GEO database that is
not annotated. Out of the 17 asthma studies examined,
only 4 had GDS annotations. These four studies con-
tained a total of 212 samples. The studies had an aver-
age of 2.333 annotations per sample. The variables that
were annotated in GDS included “agent”, “disease state”,
“time”,a n d“other”. The coverage (or the percent of the
samples containing a value for a given variable) was
examined, and the results are displayed in Table 3.
Table 4 shows all the studies’ goals and the number of
samples in each of the 17 annotated studies.
There is relatively inconsistent coverage of the GDS
data within GEO. There was a wide gap between the
variable with the highest (88.2%) and the lowest (12.7%)
percent coverage. Both “Agent” and “Time” variables
were the least covered, while “Disease State” had good
coverage.
From GEO, a total of 918 samples were examined. 26
variables in each sample were annotated, which was a
significant increase from the 4 variables that GDS cur-
rently covers. There were a total of 20,640 annotations,
but of these variables, only 10,419 had known values,
with a variable coverage of 50.5% for all variables that
were annotated.
As shown in Table 5, the majority of variables were
f o u n dt ob ep o o r l yc o v e r e d ,w i t ht h ev a r i a b l e( “Tissue”)
having a coverage of 56.1% and the poorest covered
variable (“Race”) with 0.2%. These results were typical of
most other variables, and illustrate the difficulties in
reusing data that are currently deposited into GEO.
T h ec o n s i s t e n c yo ft h es t u d i e si nt h ea s t h m ad o m a i n
was also measured. In one such study (GSE4302), the
data for 32 asthmatics randomized to a placebo-con-
t r o l l e dt r i a lo ff l u t i c a s o n ep r o p i o n a t ew e r ee x a m i n e d .
The authors use the generic name “fluticasone propio-
nate” within both the abstract and the manuscript; how-
ever the trade name “Flovent” is used within the data
deposited within GEO. Inconsistencies such as this
could prove problematic when trying to repeat a
Table 2 Inter-annotator agreement for the asthma
disease domain
Agreement Type % Agreement Kappa
Strict 93 0.859
Table 3 Coverage of Asthma variables in GDS
GSE 470 GSE 473 GSE 3183 GSE 3004 Total
Agent 100% 0% 100% 100% 17.4%
Disease State 100% 100% 0% 0% 88.2%
Time 100% 0% 100% 0% 12.7%
Other 0% 100% 0% 0% 82.5%
No. of Samples 12 175 15 10 212
Table 4 Annotated GEO asthma studies
Study No. of Samples Topic/Title
GSE8052 404 Determinants of susceptibility to childhood asthma
GSE473 175 Defining diagnostic genes from purified CD4+ blood cells that have specific diagnostic profiles
GSE4302 118 Profiling of airway epithelial cells
GSE3184 40 Murine airway hyperresponsiveness
GSE483 39 Allergic response to ragweed
GSE1301 24 Mechanisms by which IL-13 elicits the symptoms of asthma
GSE8668 24 Effects of exercise on gene expression
GSE6858 16 Expression data from experimental murine asthma
GSE3183 15 Early cytokine-mediated mechanisms that lead to asthma
GSE470 12 Asthma exacerbatory factors
GSE9465 12 Pulmonary responses to ambient particulate matter
GSE3004 10 Effects of allergen challenge on airway cell gene expression
GSE2276 9 Effect of PGE receptor subtype agonist on an asthma model
GSE476 8 Ozone effect on airways hyperpermability
GSE481 5 Allergen-induced goblet cells
GSE477 5 Alternatively activated macrophages
GSE2955 2 Transcriptional activation of AhR pathway in keratinocytes
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can be subtle differences in medications that differ in
trade name but represent the same chemical entity.
Within the studies examined, an association between
asthma diagnosis status and the use of various medica-
tions (or the lack thereof) was assessed.
Table 6 shows the different variables of asthma states
as well as the medication variables. Using Fisher’se x a c t
test, a strong association between asthma diagnosis and
the annotation of a medication variable (either “short
acting beta agonist”, “steroid inhaler”,o r“systemic ster-
oid”) was established, as shown in Table 7. This result
showed that while variable coverage may be scarce,
there was appropriate use of medication variables only
when a corresponding asthma diagnosis was present
Discussion
Gene expression repositories currently hold a large
amount of data, and are continually expanding at a
rapid rate [1]. Because of this, it is important to ensure
that data placed into repositories such as GEO contain
enough information so that they can be useful for future
analysis [17,18].
We show that for four studies with GDS annotations,
there were only 2.333 annotations per sample. More-
over, coverage appeared to be limited for two of the
variables. This can be partly explained by annotations in
GDS, which are discretionary and vary between studies
even within the same domain. For example, the coverage
for the variable “Agent” is low even with 100% coverage
in three studies with 12, 15 and 10 samples each. The
coverage is offset by 0% coverage in one big study with
175 samples. Thus, the overall coverage is diminished. It
would be desirable to have more GDS annotations for
more studies and samples to determine a more robust
estimate of variable coverage using GDS.
For the 17 studies that we annotated, we show that
there was only 50.5% variable coverage for asthma stu-
dies within GEO. The coverage is inconsistent and fluc-
tuates between different variables. Certain variables that
one might consider important for genetic asthma studies
were only annotated some of the time (such as family
history, with 20.6% coverage). Some of the coverage
issues may have been attributed to inappropriate vari-
ables used in analysis (i.e. the use of “Race” when evalu-
ating a murine model experiment). Future work may
look at identifying variables specific to individual studies
(and in a broader sense, variables specific to domains of
work), and only comparing studies within those specific
subsets.
This study demonstrated that there are key discrepan-
cies in the data deposited within GEO, but also offers evi-
d e n c et h a ti ti sp o s s i b l et or e - a n n o t a t et h ed a t aw i t h
relatively few resources in a short amount of time [12].
Re-annotation of sample datab yt w ot r a i n e da n n o t a t o r s
resulted in 93% inter-annotator agreement for asthma, and
80% inter-annotator agreement for the training domain,
breast cancer. Some of this improvement can be attributed
to familiarity with the annotation process, resulting in
committing fewer errors in annotation. In addition, there
were only 26 asthma variables, compared to 41 breast can-
cer variables for annotation. Manually searching for values
for fewer variables is an easier task, and therefore less
prone to errors and discrepancies. Overall, inter-annotator
agreement was excellent, providing reliable annotations to
determine annotation adequacy.
Only a limited number of samples were used for eva-
luation of consistency (since only one study had appro-
priate parameters). The use of “Flovent” rather than
“flucticasone propionate” could cause confusion to
annotators not familiar with the field, and, more impor-
tantly, is likely to pose difficulties to data mining soft-
ware that may be programmed to recognize some trade
names but not others. Lack of consistency may hamper
attempts to accurately extract and integrate data from
GEO, but more studies are needed to better evaluate the
Table 5 Selected examples of coverage in annotated
variables
Variable # Unknown Coverage (%)
Race 916 0.2
Age 855 6.9
Family history 729 20.6
Systemic steroid 729 20.6
Genetic deficiency 729 20.6
Steroid inhaler 697 24.1
Disease frequency 627 31.7
Gender 489 46.7
Atopic 425 53.7
Tissue 403 56.1
Challenge 0 1.0
Table 6 Association of medication use and asthma severity variables
No steroid inhaler No beta agonist Short acting beta agonist Steroid inhaler Systemic steroid Others
Mild asthma (105) 0 0 10 0 0 0
Moderate asthma (39) 0 0 0 19 0 0
Severe asthma (80) 0 0 0 0 0 0
No asthma (255) 138 138 0 0 0 0
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Other variables that could be evaluated for consistency
would be cancer staging (if there are more than one sta-
ging systems) or presence of metastases, which should
correspond to a stage four cancer. Any annotation
inconsistency should be addressed with the study inves-
tigators to avoid errors in data analysis.
There was strong association of the variables defined
as types of medication and the asthma disease state vari-
able. This finding confirms that annotations of variables
are appropriately associated with other relevant variables
(i.e. the use of medication should only being attributed
to subjects who actually have asthma, not those with-
out). Although the sample size was small, this associa-
tion was highly significant (p=0.000002), warranting
further study of variables and associations.
Conclusions
Adequate sample annotation within GEO is important
f o rd a t at ob eu s a b l eb yt h es c i e n t i f i cc o m m u n i t y .I n
particular, it is important for variables to be consistent
and to be comprehensive and include key features of the
experiment. There was inconsistency in medication
name usage, which would benefit from further studies
on consistency of sample annotations. We show that the
coverage within GEO is inadequate in the domain of
asthma, while association appears to be satisfactory.
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